NEW HOPE, Pa.--(BUSINESS WIRE)--May 4, 2006--Protalex, Inc. (OTC BB: PRTX - News) announces the successful completion of its Phase I trial of its lead compound, PRTX-100 in humans. This Phase I study was performed in healthy volunteers, and was designed primarily to assess the safety and tolerability of PRTX-100.
